Latest Settlements News

Chimeric Therapeutics remains suspended from ASX trading after failing to lodge its FY2026 financial statements, with the company reporting an approximate $7.7 million net asset deficiency and unresolved creditor negotiations. Potential recapitalisation interest has emerged, but no binding funding or settlement agreement has been reached.

Hastings Technology Metals has cut its annual loss sharply, but its latest report flags a material uncertainty over whether the pre-production rare earths company can secure the funding needed for Yangibana and its proposed Thai processing plant. The uncertainty comes as Wyloo seeks to sell its 60% Yangibana stake despite a study showing attractive project economics.

CONNEQT Health delivered sharp FY26 revenue growth and reduced its statutory loss as Pulse sales and clinical subscriptions expanded. But the ASX-listed medtech group ended the year with negative net assets, heavy cash burn and a material uncertainty over its ability to continue as a going concern.

MCS Services has completed the sale of its Traffic Business and now has no operating business, while its ASX securities remain suspended pending a possible recompliance transaction. The company reported $1.77 million in cash at 30 June 2026, but also faces a $495,000 legal settlement and no recurring operating revenue.

Indiana Resources has finished FY2026 with A$30.1 million in cash and term deposits, promising exploration results in South Australia and an unresolved dispute over 18% of its Tanzania settlement proceeds. The company is also preparing for Managing Director and CEO Matthew Bowles to leave in November.

Kingsland Minerals has advanced its flagship Leliyn Graphite Project into pre-feasibility, backed by high-grade drilling, gallium testwork and a A$2.16 million capital raising. But the ASX-listed explorer finished FY2026 with only A$458,032 in cash and remains dependent on further funding.

Noronex Limited (ASX:NRX) swung to a A$1.145 million statutory profit in FY2026, but the result was driven mainly by tenement disposal gains while operating cash outflows increased sharply. The auditor also highlighted material uncertainty over the explorer’s ability to continue without further funding.

Australian Bond Exchange Holdings improved revenue, reduced its annual loss and sharply cut operating cash outflow in FY2026. Yet with only A$249,000 in cash, net liabilities of A$1.43 million and A$2 million of convertible notes maturing from April 2027, the turnaround remains financially fragile.

Klevo Group has cut its FY2026 loss by more than three-quarters, turned operating cash flow positive and lifted cash to A$4.32 million. The ASX-listed fintech is now reporting USD 59.2 million of unaudited revenue from its post-year-end stablecoin rollout, although the figure remains difficult to reconcile with the earlier trial disclosure.

Amara Minerals has warned of a material uncertainty over its ability to continue as a going concern after reporting an $8.79 million FY2026 loss and $2.08 million in cash. The company is advancing Victorian gold-antimony exploration, but further equity funding is required and a GST-related court dispute remains unresolved.

Radiopharm Theranostics reported a A$56.3 million comprehensive loss for fiscal 2026, with operating cash outflows rising to A$52.8 million and cash falling to A$4.1 million. The company says further funding is required, while auditors flag a material uncertainty over its ability to continue as a going concern.

Quay Global’s two real estate funds delivered sharply different FY2026 results, with the unhedged fund swinging to a $22.852 million operating loss while the AUD Hedged fund recorded a $22.991 million profit. The year also brought large ETF redemptions, new currency-hedging disclosures and a major reset of Bennelong’s board after year-end.